Campath alemtuzumab: Phase II; marketed to treat B cell chronic lymphocytic leukemia (B-CLL)

ILXO has enrolled 95 patients in an open-label international Phase II trial comparing

Read the full 134 word article

How to gain access

Continue reading with a
two-week free trial.